CEL-SCI and ErgoMed Sign Co-Development and Profit Sharing Agreement for Multikine in HIV/HPV Co-Infected Men and Women With Peri-Anal Warts

Published: Oct 29, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has signed a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. for CEL-SCI’s investigational immunotherapy drug Multikine (“Leucocyte Interleukin Inj.”) in HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI has also recently entered a Cooperative Research and Development Agreement (CRADA) for this disease indication with the US Naval Medical Center, San Diego.

Help employers find you! Check out all the jobs and post your resume.

Back to news